Aptose Biosciences (APTO) News Today $0.19 -0.05 (-20.83%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.comNovember 23 at 2:29 AM | americanbankingnews.comAptose Biosciences Inc. Announces Pricing of $8 Million Public OfferingNovember 22 at 8:00 AM | globenewswire.comAptose Biosciences Inc. (NASDAQ:APTO) Issues Press Release Regarding AI-Driven Agent SARA™November 22 at 4:35 AM | americanbankingnews.comAptose Biosciences, Inc.: Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet TherapyNovember 21 at 1:14 PM | finanznachrichten.deAptose Biosciences initiates TUSCANY Phase 1/2 studyNovember 21 at 1:14 PM | markets.businessinsider.comAptose Biosciences price target lowered to $2 from $7 at H.C. WainwrightNovember 21 at 1:14 PM | markets.businessinsider.comAptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet TherapyNovember 20 at 7:30 AM | globenewswire.comAptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.comNovember 15, 2024 | americanbankingnews.comAptose Biosciences Reports Q3 2024 Financial HighlightsNovember 9, 2024 | markets.businessinsider.comAptose Biosciences Advances AML Triplet TherapyNovember 9, 2024 | markets.businessinsider.comAptose Reports Results for the Third Quarter 2024November 8, 2024 | globenewswire.comAptose Biosciences Inc (LTI.BE)September 12, 2024 | sg.finance.yahoo.comAptose Announces Results from Special Meeting of ShareholdersSeptember 5, 2024 | globenewswire.comWall Street Set to Open Shortened Week Lower Tuesday as Investors Await Manufacturing DataSeptember 4, 2024 | msn.comAptose Biosciences secures funds for AML treatment developmentSeptember 3, 2024 | finance.yahoo.comAptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop TuspetinibAugust 30, 2024 | globenewswire.comAptose Biosciences Inc: Analyst Forecasts and Stock AnalysisAugust 30, 2024 | theglobeandmail.comAptose Announces Adjournment of its Special Meeting of ShareholdersAugust 15, 2024 | globenewswire.comADMA Biologics Shares Rise 27% After 2Q Earnings Beat ExpectationsAugust 9, 2024 | marketwatch.comAptose Reports Results for the Second Quarter 2024August 8, 2024 | globenewswire.comAptose Announces Receipt of Deficiency Notice from NasdaqJuly 19, 2024 | globenewswire.comAptose Announces Results from Annual and Special Meeting of ShareholdersJune 18, 2024 | globenewswire.comAptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid CongressJune 14, 2024 | globenewswire.comAptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 3, 2024 | globenewswire.comAptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 31, 2024 | globenewswire.comAptose Reports Results for the First Quarter 2024May 14, 2024 | globenewswire.comAptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024May 6, 2024 | globenewswire.comAptose Biosciences target cut, maintains buy rating on new drug developmentMarch 29, 2024 | investing.comAptose Biosciences, Inc.: Aptose Reports Results for the Fourth Quarter and Full Year 2023March 28, 2024 | finanznachrichten.deAptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comEdgewood secures $20m in Series A for clinical development of cancer therapyMarch 27, 2024 | msn.comRecap: Aptose Biosciences Q4 EarningsMarch 27, 2024 | benzinga.comAptose Reports Results for the Fourth Quarter and Full Year 2023March 26, 2024 | globenewswire.comAptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024March 18, 2024 | globenewswire.comThis Aptose Biosciences Insider Increased Their Holding In The Last YearJanuary 29, 2024 | finance.yahoo.comAptose Biosciences Shares Drop 11% After Private, Public OfferingsJanuary 26, 2024 | marketwatch.comAptose Prices Offering Of About 4.91 Mln Shares At $1.71/Share, $4 Private Placement With HanmiJanuary 26, 2024 | markets.businessinsider.comAptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi PharmaceuticalJanuary 26, 2024 | finance.yahoo.comWhy Is Aptose Biosciences (APTO) Stock Down Today?January 26, 2024 | investorplace.comAptose Biosciences Stock (NASDAQ:APTO), Guidance and ForecastDecember 21, 2023 | benzinga.comAptose Biosciences Inc APTODecember 5, 2023 | morningstar.comAptose Biosciences files to sell ordinary shares, warrantsDecember 4, 2023 | msn.comAptose Biosciences, Inc.: Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive RoleDecember 1, 2023 | finanznachrichten.deAptose Biosciences Inc. (APTO) Q3 2023 Earnings Call TranscriptNovember 12, 2023 | seekingalpha.comAptose Biosciences Stock (NASDAQ:APTO) Earnings Dates and Earning CallsNovember 11, 2023 | benzinga.comAptose Biosciences: Q3 Earnings InsightsNovember 10, 2023 | benzinga.comPromising Financial Performance and Clinical Developments Bolster Aptose Biosciences’ Buy Rating: An Analysis by Joseph PantginisNovember 10, 2023 | markets.businessinsider.comAptose Biosciences GAAP EPS of -$1.76 beats by $0.22November 9, 2023 | msn.comOppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)November 1, 2023 | markets.businessinsider.comPromising Trial Data and Expansion Plans Boost Confidence in Aptose Biosciences: An Analysis of John Newman’s Buy RatingNovember 1, 2023 | markets.businessinsider.com Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. APTO Media Mentions By Week APTO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APTO News Sentiment▼0.200.49▲Average Medical News Sentiment APTO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APTO Articles This Week▼70▲APTO Articles Average Week Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Inhibikase Therapeutics News Today IN8bio News Today AIM ImmunoTech News Today NKGen Biotech News Today Turnstone Biologics News Today Senti Biosciences News Today Evaxion Biotech A/S News Today Coeptis Therapeutics News Today Brainstorm Cell Therapeutics News Today Organovo News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APTO) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
